grant
Targeting Glioblastoma with Multifunctional Anti-RAGE Oligonucleotides
Organization BECKMAN RESEARCH INSTITUTE/CITY OF HOPELocation DUARTE, UNITED STATESPosted 1 May 2026Deadline 30 Apr 2031
NIHUS FederalResearch GrantFY2026AGE receptorAblationAddressAdvanced Glycation End ProductsAdvanced Glycosylation End ProductsAffinityAntisense AgentAntisense OligonucleotidesBBB crossingBiodistributionBrain CancerCancersCell BodyCell Communication and SignalingCell SignalingCellsClinical TrialsCombined Modality TherapyDNA BindingDNA Binding InteractionDNA Molecular BiologyDNA boundDataDevelopmentDiagnosisDoseDrugsEndothelial CellsFrequenciesFutureGeneralized GrowthGeneticGlial Cell TumorsGlial NeoplasmGlial TumorGlioblastomaGliomaGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaGrowthHeterogeneityHortega cellHumanImmuneImmune EvasionImmune GlobulinsImmune mediated therapyImmunesImmunochemical ImmunologicImmunoglobulinsImmunologicImmunologicalImmunologicallyImmunologically Directed TherapyImmunologicsImmunotherapyIn vivo analysisIntracellular Communication and SignalingInvadedLigandsMacrophageMalignant NeoplasmsMalignant TumorMalignant Tumor of the BrainMalignant neoplasm of brainMedicationMembraneMiceMice MammalsMicrogliaModelingModern ManMolecularMolecular BiologyMultimodal TherapyMultimodal TreatmentMurineMusMφNeuroglial NeoplasmNeuroglial TumorOligoOligonucleotidesOncogenicPDX modelPathway interactionsPatient derived xenograftPatientsPattern recognition receptorPharmaceutical PreparationsProductionPropertyProteinsRAGE receptorReceptor ActivationReceptor InhibitionReceptor ProteinRegimenResistanceRoleRouteSignal PathwaySignal TransductionSignal Transduction SystemsSignalingSpecificityTestingTherapeuticTissue GrowthTumor Cell InvasionTumor InvasionWorkacetyl-LDL receptoracetylated LDL receptoractivation productadvanced glycation endproductadvanced glycosylation end product receptoradvanced glycosylation endproductamphoterin receptoranti-tumor immune responseantisense oligobiological signal transductionblood-brain barrier crossingbloodbrain barrier crossingcancer microenvironmentcheck point blockadecheckpoint blockadecombination therapycombined modality treatmentcombined treatmentdesigndesigningdetermine efficacydevelopmentaldrug/agentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationefficacy studyevaluate efficacyexamine efficacyexperimentexperimental researchexperimental studyexperimentsextracellulargitter cellglial-derived tumorglioblastoma multiformeglioma cell lineglycationimmune check point blockadeimmune checkpoint blockadeimmune evasiveimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunoneurologyimprovedin vivoin vivo evaluationin vivo testinginhibitormalignancymembermembrane structuremesogliamicroglial cellmicrogliocytemulti-modal therapymulti-modal treatmentmultidisciplinaryneoplasm/cancerneuro-oncologyneuroglia neoplasmneuroglia tumorneuroimmunologyneurooncologynew approachesnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnon-enzymatic glycosylationnonenzymatic glycosylationnovelnovel approachesnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel strategiesnovel strategynovel therapeuticsnovel therapyoligosontogenyoxidationpathwaypatient derived xenograft modelperivascular glial cellpermissivenesspre-clinical studypreclinical studyreceptorreceptor for AGEreceptor for advanced glycation end productreceptor for advanced glycation endproductsreceptor of AGEresistance mechanismresistance to therapyresistantresistant mechanismresistant to therapyresponsescavenger receptorsmall moleculesocial rolespongioblastoma multiformesuccesssynergismtargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic resistancetherapy resistanttreatment resistancetreatment strategytumortumor growthtumor microenvironment
Description preview
PROJECT SUMMARY
Patients diagnosed with glioblastoma (GBM) have a median overall survival of less than two years even
after receiving multimodal therapies. Multiple factors account for treatment resistance including: 1) Inability of
therapies to cross the blood-brain barrier to reach invading cells; 2) GBM’s molecular heterogeneity and…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click